We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Janssen

News List

Janssen announces two-drug combination of dolutegravir and rilpivirine demonstrates efficacy in main pharmaasia
March 06, 2017
Positive results of switching patients from a three or four drug antiretroviral regimen to the two-drug regimen of dolutegravir and rilpivirine
EMA recommends expanded indication for Janssen multiple myeloma drug pharmafile
February 28, 2017
The European Medicines Agency’s Committee for Medicinal Products for Human Use has given its positive opinion for the use of Janssen’s CD38-directed monoclonal antibody Darzalex (daratumumab).
Renova takes over rights to heart failure candidate stresscopin from Janssen pharmaceutical-technology
February 09, 2017
US-based Renova Therapeutics has signed an agreement to receive the investigational new drug (IND) file for stresscopin from Janssen Pharmaceuticals.
Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation o americanpharmaceuticalreview
February 06, 2017
Janssen Research & Development has announced several new collaborations through its Janssen Human Microbiome Institute (JHMI) focused on advancing the discovery, development and commercialization of next-generation microbial products.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page